Impaired Glucose ToleranceMETTIMENCT04018105
Influence of Preprandial Metformin Administration on Carbohydrate Absorption
A study testing Oral glucose tolerance test (OGTT) with or without metformin in people with Impaired Glucose Tolerance and Type2 Diabetes, run by University Hospital, Lille.
Trial summary
Type 2 diabetes is spreading worldwide as well as obesity. Metformin is the most prescribed antidiabetic medication. One suggested mechanism of action is by decreasing carbohydrate absorption. It is usually recommended to take metformin during the meal to decrease gastrointestinal side effects. Read more about this study
- Who is it for?
- Ages 18 to 60 years, women only
- Conditions the study is for
- Impaired Glucose Tolerance, Type2 Diabetes
- What is being tested?
- Oral glucose tolerance test (OGTT) with or without metformin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1 participants
- Where
- No sites listed yet
- Study dates
- 28 Jul 2021to 5 Apr 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Obesity (BMI ≥30 kg/m2)
- Dysglycemia (HbA1c≥ 6,0 %)
- No anti diabetic medication
Who cannot join
- No obesity (BMI < 30 kg/m2)
- No dysglycemia (HbA1c <6,0%)
- Treatment that might interfere with carbohydrate absorption (anti diabetic medication, antibiotics, probiotics, steroids)
- Anemia (Hb <12 g/dL)
- Organ failure
- Inflammatory Bowel Disease
About this study
Official title: Influence of Preprandial Metformin Administration on Carbohydrate Absorption: Pilot Randomized Controlled Study
Type 2 diabetes is spreading worldwide as well as obesity. Metformin is the most prescribed antidiabetic medication. One suggested mechanism of action is by decreasing carbohydrate absorption.
It is usually recommended to take metformin during the meal to decrease gastrointestinal side effects. However, if metformin decreases carbohydrate absorption, this might not be the most efficient intake.
To study the influence of preprandial metformin administration on carbohydrate absorption, it will repeat 3 oral glucose tolerance test on obese dysglycemic patients, without metformin or with metformin administer 30 or 60 minutes before. We will also evaluate how it impacts gastrointestinal tolerance.
- Conditions
- Impaired Glucose Tolerance, Type2 Diabetes
- Being tested
- Oral glucose tolerance test (OGTT) with or without metformin
- Keywords
- Impaired glucose tolerance, type 2 diabetes, obesity, carbohydrate absorption, metformin
- Medical subject headings
- Glucose Intolerance, Diabetes Mellitus, Type 2, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oral glucose tolerance test (OGTT) with or without metforminOther
Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.
| Study group | Role | What they receive |
|---|---|---|
| taking metformin 30 or 60 minutes before the OGTT | Experimental | Not described Receives: Other: Oral glucose tolerance test (OGTT) with or without metformin |
| No metformin before OGTT | Placebo comparator | Not described Receives: Other: Oral glucose tolerance test (OGTT) with or without metformin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area under the curve of D-Xylose
Measured: During the 3 hours OGTT
Secondary outcomes (4)
Number of Participants with gastrointestinal side effects
Measured: During the 3 hours OGTT
Area under the curve of blood glucose
Measured: During the 3 hours OGTT
Area under the curve of insulin
Measured: During the 3 hours OGTT
Area under the curve of GLP-1
Measured: During the 3 hours OGTT
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jul 2019
- Study start28 Jul 2021
- Primary completion4 Apr 2025
- Study completion5 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Impaired Glucose ToleranceStudies of the same condition, open and under way.
- More trials run by University Hospital, LilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Lille
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- camille Marciniak, MD, Principal investigator, University Hospital, Lille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04018105
- Sponsor's protocol ID
- 2018_35
- Other IDs
- 2019-001175-36, 2019
- Acronym
- METTIME
- Status last verified
- Dec 2025
- First submitted
- 10 Jul 2019
- Last updated
- 22 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Influence of Preprandial Metformin Administration on Carbohydrate Absorption: Pilot Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT04018105
- Acronym / sponsor ID
- METTIME / 2018_35
- Conditions
- Impaired Glucose Tolerance, Type2 Diabetes
- Keywords
- Impaired glucose tolerance, type 2 diabetes, obesity, carbohydrate absorption, metformin
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1 participants (actual)
- Lead sponsor
- University Hospital, LilleUniversity, hospital or other
- Study start
- 28 Jul 2021 (actual)
- Primary completion
- 4 Apr 2025 (actual)
- Study completion
- 5 Apr 2025 (actual)
- First posted
- 12 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Type 2 diabetes is spreading worldwide as well as obesity. Metformin is the most prescribed antidiabetic medication. One suggested mechanism of action is by decreasing carbohydrate absorption.
It is usually recommended to take metformin during the meal to decrease gastrointestinal side effects. However, if metformin decreases carbohydrate absorption, this might not be the most efficient intake.
To study the influence of preprandial metformin administration on carbohydrate absorption, it will repeat 3 oral glucose tolerance test on obese dysglycemic patients, without metformin or with metformin administer 30 or 60 minutes before. We will also evaluate how it impacts gastrointestinal tolerance.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| taking metformin 30 or 60 minutes before the OGTT | Experimental | Other: Oral glucose tolerance test (OGTT) with or without metformin |
| No metformin before OGTT | Placebo comparator | Other: Oral glucose tolerance test (OGTT) with or without metformin |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Obesity (BMI ≥30 kg/m2)
- Dysglycemia (HbA1c≥ 6,0 %)
- No anti diabetic medication
Key exclusion criteria (6 listed)
- No obesity (BMI < 30 kg/m2)
- No dysglycemia (HbA1c <6,0%)
- Treatment that might interfere with carbohydrate absorption (anti diabetic medication, antibiotics, probiotics, steroids)
- Anemia (Hb <12 g/dL)
- Organ failure
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oral glucose tolerance test (OGTT) with or without metforminEach participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized. | Other | No metformin before OGTT, taking metformin 30 or 60 minutes before the OGTT |
Primary outcome
Area under the curve of D-Xylose
Time frame: During the 3 hours OGTT
4 secondary outcomes
Number of Participants with gastrointestinal side effects
Time frame: During the 3 hours OGTT
Area under the curve of blood glucose
Time frame: During the 3 hours OGTT
Area under the curve of insulin
Time frame: During the 3 hours OGTT
Area under the curve of GLP-1
Time frame: During the 3 hours OGTT
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2026.
Related trials for Impaired Glucose Tolerance
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
RecruitingObservational study
Food-i-Sense Analytics: Integrating AI Into Continuous Glucose Monitoring Data Analysis for Precision Nutrition.
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Artificial Intelligence Mobile Application
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Recruiting
CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes
PreDiabetes
Active, not recruitingPhase 2
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Cushing Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
camille Marciniak, MD principal investigator
University Hospital, Lille
Questions about this trial
What is this clinical trial studying?
A study testing Oral glucose tolerance test (OGTT) with or without metformin in people with Impaired Glucose Tolerance and Type2 Diabetes, run by University Hospital, Lille.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area under the curve of D-Xylose (time frame: During the 3 hours OGTT). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.